Methods
Our study concentrated on analyzing the information collected from a prospectively observational registry of AF ablation procedures conducted at our institution, which has been documented in the Chinese Clinical Trial Registry (ChiCTR-OCH-14004674)15. The research received approval from the local Institutional Review Board, ensuring that all study participants provided written informed consent. The primary objective of the study was to assess two key outcomes: the recurrence rate of AF and the incidence of MACCE, which include stroke, TIAs, systemic embolic events, acute myocardial infarction, advanced heart failure, and mortality. We also tracked significant bleeding episodes and instances of patient hospital readmission. Study inclusion criteria mandated that participants must have undergone an AF catheter ablation at our institution between January 2015 and December 2020. Exclusions applied to those who were: (i) below 18 years of age, (ii) monitored for less than a one-year period post-ablation, or (iii) diagnosed with mitral valvular heart disease. Baseline demographic information, physical metrics including height and weight, medical histories, alcohol use patterns, and echocardiographic data were meticulously gathered and arranged. In line with contemporary protocols, we computed the CHA2DS2-VASc and HAS-BLED scores for each participant16.